E-mail: smolej@fnhk.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- A MULTICENTER, PHASE IV OBSERVATIONAL SAFETY STUDY OF OFATUMUMAB IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) STUDY
- A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study
- ACHIEVEMENT OF BCL-2/IGH NEGATIVITY IN PERIPHERAL BLOOD/BONE MARROW IS ASSOCIATED WITH BETTER CLINICAL OUTCOME IN PATIENTS WITH FOLLICULAR LYMPHOMA
- Angiogeneze u chronické lymfocytární leukémie.
- ANGIOGENIC ACTIVATORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: EFFECT OF TREATMENT WITH IMATINIB MESYLATE
- ANGIOGENIC CYTOKINES IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: ASSOCIATION WITH IGVH MUTATION STATUS AND GENETIC ABNORMALITIES
- Angiogenní cytokiny u chronické B-lymfocytární leukémie: souvislost s moderními prognostickými faktory
- Angiogenní faktory bFGF, VEGF a sCD105 jsou zvýšeny u chronické B-lymfocytární leukémie.
- ANGIOPOIETIN-2 MRNA DETECTED BY REAL-TIME QUANTITATIVE PCR IS DIFFERENTIALLY EXPRESSED IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Angiopoietin-2 mRNA Expression Is Elevated in Chronic Lymphocytic Leukemia Patients with Poor Prognostic Features
- ANGIOPOIETIN-2 MRNA EXPRESSION IS INCREASED IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH UNMUTATED IGVH GENES
- Association of IgVH mutation status and plasma levels of angiogenic activators in chronic lymphocytic leukaemia: significantly higher bFGF but not VEGF in IgVH mutated patients
- ASSOCIATION OF ZAP-70 EXPRESSION WITH PLASMA LEVELS OF ANGIOGENIC ACTIVATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
- BASIC FIBROBLAST GROWTH FACTOR (BFGF) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ARE ELEVATED IN PATIENTS WITH EARLY STAGE B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.
- Bone Marrow Angiogenesis in Chronic Lymphocytic Leukemia: Relationship to Classical and Modern Prognostic Factors
- BONE MARROW/PERIPHERAL BLOOD POSITIVITY OF BCL-2/IGH REARRANGEMENT IN PATIENTS WITH FOLLICULAR LYMPHOMA BEFORE TREATMENT HAS NO PROGNOSTIC SIGNIFICANCE
- Circulating Angiogenic Cytokines in Chronic Lymphocytic Leukemia: Relationship to Modern Prognostic Factors and Effect of Fludarabine-Based Treatment
- COMBINATION OF IGVH MUTATIONAL STATUS AND GENETIC ABNORMALITIES MAY FURTHER REFINE PROGNOSTIC STRATIFICATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- COMPLEX ACTIVATION OF ANGIOGENIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCE FROM CIRCULATING ANGIOGENIC CYTOKINES
- Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy
- Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro
- DELTA EX6, THE NOVEL TRANSACTIVATION-DEFECTIVE SPLICING VARIANT OF TP53, IS DIFFERENTIALLY EXPRESSED IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND CONFERS ACCENTED PROLIFERATIVE PHENOTYPE IN VITRO
- DIAGNOSTIC AND THERAPEUTIC APPROACH TO SMALL LYMPHOCYTIC LYMPHOMA (SLL): EXPERIENCE OF CZECH LYMPHOMA STUDY GROUP
- EFFICACY AND SAFETY OF RITUXIMAB AND HIGH-DOSE DEXAMETHASONE (R-DEX) IN THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- ENDOGLIN AS A NEW BIO INDICATOR OF HAEMORHEOPHERESIS/IMMUNOAPHERESIS PROCEDURE EFFICIENCY
- ENDOTHELIAL MICROPARTICLES AND MARKERS OF COPPER METABOLISM AS NOVEL INDICATORS OF ANGIOGENESIS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.
- Exprese fibroblastového růstového faktoru 2 u pacientů s chronickou lymfocytární leukemií
- Five-Color Multiplex Real-Time PCR Technology to Detect Over 75 Recurrent Chromosomal Abnormalities in Acute Myeloid Leukemia; Benefits for Minimal Residual Disease Detection
- FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RETROSPECTIVE ANALYSIS OF CZECH CLL STUDY GROUP
- HAEMORHEOPHERESIS IN THE TREATMENT OF MICROCIRCULATORY DISORDERS
- HEALTH RELATED QUALITY OF LIFE AND PATIENT REPORTED OUTCOMES IN PATIENTS RECEIVING OFATUMUMAB MAINTENANCE VERSUS OBSERVATION IN THE PROLONG TRIAL
- CHOICE OF ENDOTHELIAL MARKER IS CRUCIAL FOR QUANTIFICATION OF BONE MARROW MICROVESSEL DENSITY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Choice of endothelial marker is crucial for quantification of bone marrow microvessel density in chronic lymphocytic leukemia
- IDENTIFICATION OF A NOVEL, TRANSACTIVATION-DEFECTIVE SPLICING VARIANT OF P53 GENE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- IMATINIB MESYLATE SIGNIFICANTLY DECREASES PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND SOLUBLE ENDOGLIN BUT NOT BASIC FIBROBLAST GROWTH FACTOR IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- INCIDENCE, CHARACTERISTICS AND OUTCOME OF CNS INVOLVEMENT IN MANTLE CELL LYMPHOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS FROM THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK
- IS DETECTION OF CYP3A5*3 ALLELE IN CHRONIC MYELOID LEUKEMIA PATIENTS PRIOR TO TREATMENT WITH IMATINIB MESYLATE RELEVANT?
- Komplexní hodnocení angiogeneze u chronické lymfocytární leukémie
- Komplexní hodnocení angiogeneze u chronické lymfocytární leukémie.
- LÉČEBNÝ PŘÍSTUP K CHRONICKÉ LYMFOCYTÁRNÍ LEUKEMII U NEMOCNÝCH VYŠŠÍHO VĚKU S VÝZNAMNÝMI PŘIDRUŽENÝMI CHOROBAMI
- LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- LOW-DOSE FCR IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group
- LOW-DOSE FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINED WITH RITUXIMAB IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PROJECT Q-LITE OF CZECH CLL STUDY GROUP
- Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
- MICROVASCULAR DENSITY IN MULTIPLE MYELOMA, INFLUENCE ON PROGNOSIS
- Monoklonální protilátky v léčbě chronické lymfocytární leukémie.
- Nové a fenotypicky neobvyklé varianty genu p53 u pacientů s chronickou lymfocytární leukémií
- Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results
- Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life
- Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II T
- Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL.
- ORAL FLUDARABINE AND CYCLOPHOSPHAMIDE PLUS RITUXIMAB (FCR) IS A SAFE AND EFFECTIVE SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND FOLLICULAR LYMPHOMA.
- Plasma concentrations of angiogenic activators VEGF and bFGF in patients with multiple myeloma, follicular lymphoma, diffuse large B-cell lymphoma, and chronic myeloid leukemia
- PLASMA ENDOSTATIN LEVELS IN CHRONIC LYMPHOCYTIC LEUKEMIA: RELATIONSHIP TO PROGNOSTIC FACTORS
- PLASMA LEVELS OF SOLUBLE ENDOGLIN HAVE PROGNOSTIC SIGNIFICANCE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble endoglin (sCD105) in patients with chronic myeloid leukemia: impact of treatment with imatinib mesylate.
- Plasma soluble endoglin (sCD105) concentrations in patients with lymphoid malignancies – a pilot study
- Plazmatické koncentrace solubilního endoglinu mají prognostický význam u nemocných s chronickou lymfocytární leukémií
- Primární CNS lymfomy - zkušenosti centra
- Progresivní multifokální leukoencefalopatie – vzácná komplikace po podání chemoterapie a rituximabu u nemocného s lymfomem
- QUANTITATION OF MINIMAL RESIDUAL DISEASE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED FLUORESCENTLY LABELED PROBES AND REAL-TIME PCR TECHNOLOGY
- Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using LNA-Modified Fluorescently Labeled Probes and Real-Time PCR Technology.
- RETROSPECTIVE ANALYSIS OF TREATMENT OF PRIMARY PROGRESSIVE AND/OR RELAPSED HODGKIN’S DISEASE IN 1996 - 2004
- Richterův syndrom – současný pohled na diagnostiku a léčbu
- Rituximab and High-Dose Dexamethasone (R-dex) Is Effective In The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia
- RITUXIMAB IMPROVES OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE CENTRE RETROSPECTIVE STUDY
- RITUXIMAB IN COMBINATION WITH HIGH-DOSE DEXAMETHASONE: AN EFFECTIVE TREATMENT OPTION FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- RITUXIMAB INFUSION-RELATED TOXICITY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial
- SMALL LYMPHOCYTIC LYMPHOMA (SLL): RETROSPECTIVE ANALYSIS FROM THE REGISTRY OF CZECH LYMPHOMA STUDY GROUP
- Successful Treatment with Imatinib Mesylate Significantly Decreases Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Soluble Endoglin (sCD105) but Not Basic Fibroblast Growth Factor (bFGF) or Angiopoietin-2 (Ang-2) in Patients with Chro
- THE ROLE OF IMAGING METHODS IN CHRONIC LYMPHOCYTIC LEUKEMIA: SIGNIFICANT INTERNAL LYMPHADENOPATHY IS FREQUENT AND ASSOCIATED WITH SHORTER OVERALL SURVIVAL
- TP53 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 2,435 CONSECUTIVE CLL SAMPLES
- VENOUS THROMBEMBOLISM: A FREQUENT COMPLICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Zvýšená exprese mRNA pro Angiopoietin-2 u pacientů s chronickou lymfocytární leukémií a nemutovaným IgVH
